We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Simcere Pharmaceutical Grp. Simcere Pharmaceutical Grp. American Depositary Shares | NYSE:SCR | NYSE | Ordinary Share |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 9.60 | 0.00 | 00:00:00 |
From Feb 2020 to Feb 2025
NANJING, China, Nov. 1, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2013 on Thursday, November 14, 2013, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, November 14, at 9 p.m. Beijing / Hong Kong time).
To access the conference call, please dial:
|
International toll: |
+65.6723.9381 |
|
United States toll-free: |
+1.866.519.4004 |
|
United States toll: |
+1.845.675.0437 |
|
China Domestic toll: |
800.819.0121 |
|
China Domestic mobile toll: |
400.620.8038 |
|
Hong Kong toll: |
+852.2475.0994 |
Please ask to be connected to Q3 2013 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 94745140
Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.
Following the earnings conference call, an archive of the call will be available by dialing:
|
United States toll-free: |
+1.855.452.5696 |
|
United States toll: |
+1.646.254.3697 |
The passcode for replay participants is 94745140. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.
Investor and Media Contacts:
Email: ir@simcere.com
|
In Nanjing: |
In the United States: |
|
Vivien Liang |
Cindy Zheng |
|
Simcere Pharmaceutical Group |
Brunswick Group |
|
Tel: 86-25-8556-6666*8857 |
Tel: 1-212-333-3810 |
|
In Beijing: |
|
|
Yue Yu |
|
|
Brunswick Group |
|
|
Tel: 86-10-5960-8600 |
SOURCE Simcere Pharmaceutical Group
Copyright 2013 PR Newswire
1 Year Simcere Pharmaceutical Grp. Simcere Pharmaceutical Grp. American Depositary Shares Chart |
1 Month Simcere Pharmaceutical Grp. Simcere Pharmaceutical Grp. American Depositary Shares Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
